



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Demo Report

Report Issued 04/28/2022 11:44
Last Report Issued 04/28/2022 11:44

88888
Clinical Example Report
Attn: Example Reports
200 Welsh Road
Horsham, PA 19044

Patient Name 2512SP-POS
Patient ID 2512SP-POS
Chain 22001187
DOB Not Given
Sex Not Given
Workorder 22001187
Received 04/27/2022

Lab ID 22001187-001
Matrix Serum or Plasma
Patient Name 2512SP-POS
Patient ID 2512SP-POS
Container Type Clear vial

Collect Dt/Tm Not Given
Source Not Given

Approx Vol/Weight Not Given

Receipt Notes None Entered

Analysis and Comments	Result	Units	Reporting Limit	Notes
-----------------------	--------	-------	-----------------	-------

2512SP Lidocaine and Metabolite (MEGX), Serum/Plasma

Analysis by Gas Chromatography (GC)

Lidocaine	12	mcg/mL	0.50	ELEVATED
Synonym(s):	Xylocaine®			
Comment:	Substance(s) known to interfere with the identity and/or quantity of the reported result: Diphenhydramine			

Lidocaine is an amide type of anesthetic that is used as a topical and injectable analgesic, antiarrhythmic, and in resuscitative efforts. It is also used as a 'cutting' agent in some drugs of abuse, especially cocaine.

Reported antiarrhythmic range: 2-5 mcg/mL.

Monoethylglycinexylidide (MEGX)	12	mcg/mL	0.50	ELEVATED
Synonym(s):	Lidocaine Metabolite			

Results for sample 22001187-001 are continued on next page



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208

Phone: (215) 657-4900 Fax: (215) 657-2972

e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Lab ID 22001187-001
Matrix Serum or Plasma
Patient Name 2512SP-POS
Patient ID 2512SP-POS

Collect Dt/Tm Not Given
Source Not Given

Analysis and Comments	Result	Units	Reporting Limit	Notes
-----------------------	--------	-------	-----------------	-------

MEGX (monoethylglycinexylidide) is an active metabolite of lidocaine.

Following a Lidocaine I.V. infusion at rates varying between 20 and 50 mcg/min/kg, steady-state MEGX serum concentrations range from 0.2-5.2 mcg/mL.

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.